By otakuyassine3@gmail.com 
Canaan Partners XI LLC lowered its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) by 5.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,179,857 shares of the company’s stock after selling 230,134 shares during the quarter. Tyra Biosciences accounts for 75.2% of Canaan Partners XI LLC’s holdings, making the stock its biggest holding. Canaan Partners XI LLC owned approximately 8.26% of Tyra Biosciences worth $58,100,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. increased its position in Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock valued at $2,723,000 after acquiring an additional 145,346 shares during the last quarter. Perceptive Advisors LLC raised its position in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after purchasing an additional 338,208 shares during the period. SG Americas Securities LLC bought a new stake in Tyra Biosciences in the third quarter worth about $311,000. Oppenheimer & Co. Inc. lifted its stake in Tyra Biosciences by 9.0% in the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock worth $1,806,000 after purchasing an additional 6,318 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Tyra Biosciences during the third quarter valued at approximately $491,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Tyra Biosciences Trading Down 2.2 %
Shares of Tyra Biosciences stock opened at $15.88 on Friday. The firm’s 50-day moving average is $15.38 and its two-hundred day moving average is $19.14. Tyra Biosciences, Inc. has a 1 year low of $12.34 and a 1 year high of $29.60.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.
Insider Activity
In other news, CFO Alan Fuhrman purchased 9,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the acquisition, the chief financial officer now owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 283.67 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $16.17, for a total transaction of $179,131.26. Following the completion of the transaction, the director now directly owns 472,207 shares in the company, valued at approximately $7,635,587.19. The trade was a 2.29 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,419 shares of company stock worth $844,763. 15.40% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, January 13th. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $30.50.
Get Our Latest Research Report on Tyra Biosciences
Tyra Biosciences Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Recommended Stories
Receive News & Ratings for Tyra Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tyra Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.